GlassScriptPhysician profile
Benton Michael Oubre
NPI 1457326522
$6,228.81
in general payments reported to CMS, 2019-2025
41 companies · $1,113 in 2025
The $1,113 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $777 · 2021: $749 · 2022: $835 · 2023: $971 · 2024: $746 · 2025: $1,113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,830.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,848.12 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $692.09 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $475.35 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $465.57 | 2019-2024 | Stelara |
| Celgene Corporation | $318.07 | 2022-2024 | Zeposia |
| Pfizer INC. | $291.70 | 2019-2025 | |
| Ardelyx, INC. | $279.90 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $175.31 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $172.89 | 2019-2024 | Rebyota |
| Gilead Sciences, INC. | $136.09 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $121.65 | 2019-2023 | Ocaliva |
| Celltrion USA INC. | $96.58 | 2024-2025 | Vegzelma |
| Glaxosmithkline, LLC. | $84.77 | 2019-2020 | |
| Madrigal Pharmaceuticals | $84.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Pharmacosmos Therapeutics INC. | $83.62 | 2021-2023 | Monoferric |
Show all 39 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benton Oubre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.